26 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease.
Tehran University of Medical Sciences
Synthesis and structure-activity relationship study of tacrine-based pyrano[2,3-c]pyrazoles targeting AChE/BuChE and 15-LOX.
Tehran University of Medical Sciences
Potent acetylcholinesterase inhibitors: design, synthesis, biological evaluation, and docking study of acridone linked to 1,2,3-triazole derivatives.
Tehran University of Medical Sciences
New tetracyclic tacrine analogs containing pyrano[2,3-c]pyrazole: efficient synthesis, biological assessment and docking simulation study.
Tehran University of Medical Sciences
Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives.
Tehran University of Medical Sciences
Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3',4':5,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase.
Tehran University of Medical Sciences
Design, synthesis, biological evaluation and docking study of 5-oxo-4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
Tehran University of Medical Sciences
Phenylimino-2H-chromen-3-carboxamide derivatives as novel small molecule inhibitors ofß-secretase (BACE1).
Tehran University of Medical Sciences
Synthesis, cyclooxygenase inhibitory effects, and molecular modeling study of 4-aryl-5-(4-(methylsulfonyl)phenyl)-2-alkylthio and -2-alkylsulfonyl-1H-imidazole derivatives.
Tehran University of Medical Sciences
Validated QSAR analysis of some diaryl substituted pyrazoles as CCR2 inhibitors by various linear and nonlinear multivariate chemometrics methods.
Tehran University of Medical Sciences
Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium derivatives.
Tehran University of Medical Sciences
Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.
Tehran University of Medical Sciences
A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease.
Tehran University of Medical Sciences
A review: Biologically active 3,4-heterocycle-fused coumarins.
Tehran University of Medical Sciences
Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
Tehran University of Medical Sciences
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.
Tehran University of Medical Sciences
Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
Tehran University of Medical Sciences
New racemic annulated pyrazolo[1,2-b]phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease.
Tehran University of Medical Sciences
Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities.
Tehran University of Medical Sciences
Design, synthesis and evaluation of novel multi-target-directed ligands for treatment of Alzheimer's disease based on coumarin and lipoic acid scaffolds.
Tehran University of Medical Sciences
Synthesis, docking study and neuroprotective effects of some novel pyrano[3,2-c]chromene derivatives bearing morpholine/phenylpiperazine moiety.
Tehran University of Medical Sciences
Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors.
Tehran University of Medical Sciences
Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof
Bayer Intellectual Property
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
Universit&Aagrov
Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Smithkline Beecham Pharmaceuticals